Cholestasis and Endogenous Opioids
Author:
- 1 January 2007
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 46 (10) , 825-850
Abstract
A class of endogenous Opioids is upregulated in liver disease particular to cholestasis, which contributes to symptoms in liver disease such as pruritus, hypotension and encephalopathy. Symptoms...Keywords
This publication has 202 references indexed in Scilit:
- Carrier-mediated processes at several rat brain interfaces determine the neuropharmacokinetics of morphine and morphine-6-β-d-glucuronideLife Sciences, 2006
- Medical Palliation of the Jaundiced Patient with PruritusGastroenterology Clinics of North America, 2006
- Differential effects of ammonia on the benzodiazepine modulatory site on the GABA-A receptor complex of human brainNeurochemistry International, 2005
- OxycodoneJournal of Pain and Symptom Management, 2005
- Obstructive cholestasis alters intestinal transit in mice: role of opioid systemLife Sciences, 2004
- Hydromorphone-3-glucuronideLife Sciences, 2001
- Clinical Pharmacokinetics of Alfentanil, Fentanyl and SufentanilClinical Pharmacokinetics, 1996
- Lack of Hepatotoxicity with Naltrexone TreatmentThe Journal of Clinical Pharmacology, 1994
- Plasma Concentrations and Renal Clearance of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Cancer Patients Receiving MorphineClinical Pharmacokinetics, 1993
- Drug Administration in Hepatic DiseaseNew England Journal of Medicine, 1983